Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women

Cancer

Volumn 115, Issue 17, 2009, Pages 3848-3857

  Hershman, Dawn L ^a,b,c   Buono, Donna ^c   McBride, Russell B ^c   Tsai, Wei Yann ^c   Neugut, Alfred I ^b,c  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b Columbia University ^*  (United States)

^c NONE   (United States)

Author keywords

Breast cancer; Chemotherapy; Elderly patient; Oncology; Private practice

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

AGED; AGING; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MEDICAL SPECIALIST; PRIORITY JOURNAL; PRIVATE PRACTICE; RISK ASSESSMENT; UNITED STATES;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; FEMALE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PROFESSIONAL PRACTICE; SEER PROGRAM; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 69249144492     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24448     Document Type: Article

References (34)

1. NIH consensus conference. Treatment of early-stage breast cancer. JAMA. 1991;265:391-395.
2. Carlson RW, Goldstein LJ, Gradishar WJ, et al. NCCN Breast Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996;10(11 suppl):47-75.
3. Consensus Conference. Adjuvant chemotherapy for breast cancer. JAMA. 1985;254:3461-3463.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
5. Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003;138:90-97.
6. Woodard S, Nadella PC, Kotur L, Wilson J, Burak WE, Shapiro CL. Older women with breast carcinoma are less likely to receive adjuvant chemotherapy: evidence of possible age bias? Cancer. 2003;98:1141-1149.
7. Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006;24:2757-2764.
8. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24:2750-2756.
9. Du XL, Jones DV, Zhang D. Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women. J Gerontol A Biol Sci Med Sci. 2005;60:1137-1144.
10. Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293:1073-1081.
11. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8 suppl):IV-55-IV-61.
12. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 suppl):IV-3-IV-18.
13. Baldwin LM, Adamache W, Klabunde CN, Kenward K, Dahlman C, Warren J. Linking physician characteristics and medicare claims data: issues in data availability, quality, and measurement. Med Care. 2002;40(8 suppl):IV-82-IV-95.
14. American Medical Association (AMA). Division of Survey and Data Resources. Physician master file. 2007.
15. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002;20:4636-4642.
16. Du XL, Fang S, Vernon SW, et al. Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer. 2007;110:660-669.
17. Charlson ME, Sax FL, MacKenzie CR, Fields SD, Braham RL, Douglas RG Jr. Assessing illness severity: does clinical judgment work? J Chronic Dis. 1986;39:439-452.
18. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267.
19. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44:1049-1060.
20. Panageas KS, Schrag D, Russell Localio A, Venkatraman ES, Begg CB. Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size. Stat Med. 2006;26:2017-2035.
21. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006;98:839-845.
22. Hershman DL, Buono D, McBride RB, et al. Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer. J Natl Cancer Inst. 2008;100:199-206.
23. Luo R, Giordano SH, Zhang DD, Freeman J, Goodwin JS. The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist. Cancer. 2007;109:975-982.
24. Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol. 2002;20:1786-1792.
25. Franks P, Williams GC, Zwanziger J, Mooney C, Sorbero M. Why do physicians vary so widely in their referral rates?J Gen Intern Med. 2000;15:163-168.
26. Freiman MP. The rate of adoption of new procedures among physicians. The impact of specialty and practice characteristics. Med Care. 1985;23:939-945.
27. Shen J, Andersen R, Brook R, Kominski G, Albert PS, Wenger N. The effects of payment method on clinical decision-making: physician responses to clinical scenarios. Med Care. 2004;42:297-302.
28. Mort EA, Edwards JN, Emmons DW, Convery K, Blumenthal D. Physician response to patient insurance status in ambulatory care clinical decision-making. Implications for quality of care. Med Care. 1996;34:783-797.
29. Hickson GB, Altemeier WA, Perrin JM. Physician reimbursement by salary or fee-for-service: effect on physician practice behavior in a randomized prospective study. Pediatrics. 1987;80:344-350.
30. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006;11:90-95.
31. Schrag D, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007;25:233-237.
32. Abelson R. Drug sales bring huge profits, and scrutiny, to cancer doctors. New York Times (Business Section); Jan. 26, 2003.
33. Bloom BS, de Pouvourville N, Chhatre S, Jayadevappa R, Weinberg D. Breast cancer treatment in clinical practice compared to best evidence and practice guidelines. Br J Cancer. 2004;90:26-30.
34. Bickell NA, McEvoy MD. Physicians' reasons for failing to deliver effective breast cancer care: a framework for underuse. Med Care. 2003;41:442-446.